FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1620-1630 April 19, 2007 Number 16 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce atherosclerotic vascular disease by increasing levels of high-density lipoprotein (HDL) cholesterol.

Methods A total of 850 patients with heterozygous familial hypercholesterolemia underwent B-mode ultrasonography at baseline and at follow-up to measure changes in carotid intima–media thickness. The patients completed an atorvastatin run-in period and were subsequently randomly assigned to receive either atorvastatin monotherapy or atorvastatin combined with 60 mg of torcetrapib for 2 years.

Results After 24 months, in the atorvastatin-only group, the mean (±SD) HDL cholesterol level was 52.4±13.5 mg per deciliter and the mean low-density lipoprotein (LDL) cholesterol level was 143.2±42.2 mg per deciliter, as compared with 81.5±22.6 mg per deciliter and 115.1±48.5 mg per deciliter, respectively, in the torcetrapib–atorvastatin group. During the study, average systolic blood pressure increased by 2.8 mm Hg in the torcetrapib–atorvastatin group, as compared with the atorvastatin-only group. The increase in maximum carotid intima–media thickness, the primary measure of efficacy, was 0.0053±0.0028 mm per year in the atorvastatin-only group and 0.0047±0.0028 mm per year in the torcetrapib–atorvastatin group (P=0.87). The secondary efficacy measure, annualized change in mean carotid intima–media thickness for the common carotid artery, indicated a decrease of 0.0014 mm per year in the atorvastatin-only group, as compared with an increase of 0.0038 mm per year in the torcetrapib–atorvastatin group (P=0.005).

Conclusions In patients with familial hypercholesterolemia, the use of torcetrapib with atorvastatin, as compared with atorvastatin alone, did not result in further reduction of progression of atherosclerosis, as assessed by a combined measure of carotid arterial-wall thickness, and was associated with progression of disease in the common carotid segment. These effects occurred despite a large increase in HDL cholesterol levels and a substantial decrease in levels of LDL cholesterol and triglycerides. (ClinicalTrials.gov number, NCT00136981 [ClinicalTrials.gov] .)

Source Information

From the Academic Medical Center, University of Amsterdam, Amsterdam (J.J.P.K., S.I.L., J.A.K.); Tygerberg Hospital and Stellenbosch University, Tygerberg, South Africa (L.B.); Wake Forest University, Winston-Salem, NC (G.W.E., W.A.R.); the Heart Research Institute, Sydney (P.J.B.); Pfizer, New London, CT (J.H.R., C.L.S., W.T.D.); and the Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands (D.E.G., M.L.B.).

Drs. Kastelein and Bots contributed equally to this article.

This article (10.1056/NEJMoa071359) was published at www.nejm.org on March 26, 2007.

Address reprint requests to Dr. Kastelein at the Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, Room F4-159.2, 1105 AZ, Amsterdam, the Netherlands, or at j.j.kastelein{at}amc.uva.nl.

Full Text of this Article

This article has been cited by other articles:

• Wild, S., Byrne, C. D (2008). Time to rethink high-density lipoprotein?. Heart 94: 692-694 [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94: 706-714 [Abstract] [Full Text]  
• de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W.A., Gautier, T., van der Hoogt, C. C., Westerterp, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M.G., Rensen, P. C.N. (2008). Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation 117: 2515-2522 [Abstract] [Full Text]  
• Movva, R., Rader, D. J. (2008). Laboratory Assessment of HDL Heterogeneity and Function. Clin. Chem. 54: 788-800 [Abstract] [Full Text]  
• Brown, B. G., Taylor, A. J. (2008). Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe?. NEJM 358: 1504-1507 [Full Text]  
• Kastelein, J. J.P., Akdim, F., Stroes, E. S.G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F.H., Visseren, F. L.J., Sijbrands, E. J.G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., de Groot, E., the ENHANCE Investigators, (2008). Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. NEJM 358: 1431-1443 [Abstract] [Full Text]  
• Kastelein, J. J.P., de Groot, E. (2008). Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 29: 849-858 [Abstract] [Full Text]  
• Sanz, J., Moreno, P. R., Fuster, V. (2008). The year in atherothrombosis.. J Am Coll Cardiol 51: 944-955 [Full Text]  
• Ferns, G., Keti, V. (2008). HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem 45: 122-128 [Abstract] [Full Text]  
• van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S.G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G., Pedersen, T. R., Khaw, K.-T., Kastelein, J. J.P. (2008). High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.. J Am Coll Cardiol 51: 634-642 [Abstract] [Full Text]  
• Lavie, C. J., Milani, R. V. (2008). Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.. J Am Coll Cardiol 51: 56-58 [Full Text]  
• Guerin, M., Le Goff, W., Duchene, E., Julia, Z., Nguyen, T., Thuren, T., Shear, C. L., Chapman, M. J. (2008). Inhibition of CETP by Torcetrapib Attenuates the Atherogenicity of Postprandial TG-Rich Lipoproteins in Type IIB Hyperlipidemia. Arterioscler. Thromb. Vasc. Bio. 28: 148-154 [Abstract] [Full Text]  
• Rader, D. J. (2007). Illuminating HDL -- Is It Still a Viable Therapeutic Target?. NEJM 357: 2180-2183 [Full Text]  
• Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J.P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., Brewer, B., the ILLUMINATE Investigators, (2007). Effects of Torcetrapib in Patients at High Risk for Coronary Events. NEJM 357: 2109-2122 [Abstract] [Full Text]  
• Zeller, M., Masson, D., Farnier, M., Lorgis, L., Deckert, V., Pais de Barros, J.-P., Desrumaux, C., Sicard, P., Grober, J., Blache, D., Gambert, P., Rochette, L., Cottin, Y., Lagrost, L. (2007). High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 50: 1948-1955 [Abstract] [Full Text]  
• Cuchel, M., Rader, D. J. (2007). Is the Cholesteryl Ester Transfer Protein Proatherogenic or Antiatherogenic in Humans?. J Am Coll Cardiol 50: 1956-1958 [Full Text]  
• Anantharamaiah, G. M., Mishra, V. K., Garber, D. W., Datta, G., Handattu, S. P., Palgunachari, M. N., Chaddha, M., Navab, M., Reddy, S. T., Segrest, J. P., Fogelman, A. M. (2007). Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48: 1915-1923 [Abstract] [Full Text]  
• Tuzcu, E. M., Starling, R. C., Thomas, J. D. (2007). Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts.. J Am Coll Cardiol 50: C2-31 [Full Text]  
• Singh, I. M., Shishehbor, M. H., Ansell, B. J. (2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA 298: 786-798 [Abstract] [Full Text]  
• Lehman, R. (2007). Evidently.... Evid. Based Med. 12: 103-103 [Full Text]  
• (2007). Other articles noted. Evid. Based Med. 12: 127-128 [Full Text]  
• Nieland, T. J. F., Shaw, J. T., Jaipuri, F. A., Maliga, Z., Duffner, J. L., Koehler, A. N., Krieger, M. (2007). Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. J. Lipid Res. 48: 1832-1845 [Abstract] [Full Text]